Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
In summary we propose a model
2022-01-13

In summary, we propose a model that explains the possible mechanism the HULC mediates activation of HBV in liver cancer pdgfr inhibitor (Fig. 8). In the model, HULC promotes the expression of miR-539 by stimulating HBx-co-activated STAT3. Then, miR-539 down-regulates APOBEC3B, leading to an increas
-
The GPR receptor is also
2022-01-13

The GPR55 receptor is also emerging as an important therapeutic target. GPR55−/− mice possess no overt phenotype, but were protected in models of inflammatory and neuropathic pain (Staton et al., 2008). Staton et al. (2008) reported that no GPR55 mRNA could be detected by RT-PCR in the animals. Also
-
br Conclusion br Author statement br Acknowledgments br Intr
2022-01-13

Conclusion Author statement Acknowledgments Introduction The hypothalamic-pituitary-gonadal (HPG) axis is an important neurohormone network for vertebrates that regulates their gonadal development and maturation, guarantees their pubertal development and maintains their normal reproducti
-
br Conclusion br Acknowledgments br Introduction The gyloxal
2022-01-13

Conclusion Acknowledgments Introduction The gyloxalase pathway is a well-conserved antioxidant defense system found in all cells of the body [1], [2], [3], [4]. The glyoxalase pathway facilitates the neutralization of highly reactive and oxidizing dicarbonyl molecules, with methylglyoxal (M
-
Abnormal expression and higher activity of GLO
2022-01-13

Abnormal expression and higher activity of GLO I have been detected more in various tumor Phosphate Colorimetric Assay Kit than in normal cell samples., , , , , , , Among cancer cell lines, lung carcinoma cells frequently showed higher GLO1 activity. Human NSCLC cell line NCI-H522 cells possess hi
-
br Acknowledgements We thank LetPub www
2022-01-13

Acknowledgements We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript. This work was funded by National Natural Science Foundation of Beijing (No. 7122187), and Special fund for clinical research of Chinese Medical Association (No. 13040700455).
-
br Introduction Glucokinase GCK hexokinase IV is
2022-01-12

Introduction Glucokinase (GCK, hexokinase IV) is a monomeric enzyme that catalyzes the ATP-dependent conversion of glucose to glucose 6-phosphate, the first and rate-limiting step of glycolysis in the liver and pancreas [1,2]. GCK was first discovered in the early 1960's, and shortly thereafter i
-
While the apparent complexity of gap
2022-01-12

While the apparent complexity of gap junction regulation presents challenges, new technologies continue to propel the field forward. Advances in microscopy are increasingly able to capture rapid dynamics at the plasma membrane (e.g., biosensors [67] and lattice light sheet microscopy [100]) and to d
-
The C terminal regions in both
2022-01-12

The C-terminal regions in both FGF19 and FGF21 define their KLB interaction [15], [16], [23], [25]. However, less than 40% identity in comparative alignment of C-terminal sequences for these two proteins (Table 1) suggests that their interaction with KLB may require higher-order association with oth
-
brdu Another TKI used in cancer therapy
2022-01-12

Another TKI used in cancer therapy is the Abl inhibitor imatinib mesilate which has also a beneficial effect on glucose homeostasis in diabetic humans [39], [40], [41]. Imatinib has a clear impact on NFκB activation and anti-apoptotic preconditioning of β-cells [39], attenuating islet inflammation [
-
The ability of GPX and other selenoproteins to be
2022-01-12

The ability of GPX4 and other selenoproteins to be selectively induced by ferroptotic stimuli suggests that the stress-induced increase in the transcription of a number of putative, “antioxidant” selenoproteins is an adaptive homeostatic, but insufficient response to prevent cell death in the face o
-
Interestingly the subcellular localization of FBPase
2022-01-12

Interestingly, the subcellular localization of FBPase in hepatocytes and proximal tubule AP1903 reveals that FBPase is also able to translocate to the nucleus in these cell types. The nuclear localization of muscle-FBPase was recently reported [35]. This data corroborate our results on the ability
-
The membrane metalloendopeptidase MME gene is located at hum
2022-01-12

The membrane metalloendopeptidase (MME) gene is located at human chromosome 3q21-27. It encodes a 100-kD type II transmembrane glycoprotein, a widely expressed membrane metalloendopeptidase that degrades a number of substrates. The active site of the enzyme faces the extracellular space. MME is wide
-
Another level of complexity within the TGF
2022-01-12

Another level of complexity within the TGF-ß/SMAD and Hippo/YAP/TAZ pathway crosstalks was recently uncovered. TGF-ß induces robust TAZ, but not YAP, protein expression in both mesenchymal and epithelial XAV939 through a SMAD3-independent, p38/MAPK-dependent mechanism that triggers myocardin-relate
-
ICLs represent of all generated DNA adducts for cisplatin an
2022-01-12

ICLs represent ICL Inducers in Cancer Therapy Nitrogen mustards with aromatic substituents (chlorambucil, melphalan) or a bioactivatable phosphoramide group (cyclophosphamide) were one of the first identified DNA crosslinkers. These agents are still used in combined schemes for the therapy of chr
15704 records 551/1047 page Previous Next First page 上5页 551552553554555 下5页 Last page